Up Pre-Market BSQR..Up 23%..3.89 High Volume Could be another Short Squeeze On June 29 reached High of 8.20 with a Volume of 240 million Friday volume 3.9 million
Another possible Short Squeeze with unusual heavy volume AGRI..Up 21%..4.02 Friday Volume 5 million Prior Average 500K-1 million July 9 reached High of 8.45 with 20 million Volume
On again Off again Reddit Meme MRIN..Down 8% Pre-Market 7.92 Thursday Volume 2.3 million Friday Volume 58 million Low last week 6.19 High last week..Friday 9.50 Bottom seems to be 6.25-6.50
Pre-Market King EVK..Up 77%..4.01 Up on legit news Last night Ever-Glory announced 5 million dollar stock repurchase program
SRNE..8.30 Sorrento this morning announced received FDA Authorization to start Phase 1 Clinical trial of Proprietary Allogenic anti-CD38 Dar-T Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma
TipRanks Strong buy AXSM..50.32..Axsome Therapeutics Biopharm working on new medication therapies for diseases of the central nervous system Has four drug candidates Leading Drug AXS-05 developed to treat major depressive disorder, Alzheimer's-related agitation and smoking cessation AXS-7 drug for migraine treatment ..This candidate has demonstrated effective pain relief in patients within two hours of dosing..And has a potential base of 37 million Low float 25 million Target price 135.33
News At Midnight Could soar this Morning RLFTF..Relief Therapeutics...24 Relief Announced Receipt Of US FDA Orphan Drug Designation For The Use Of RLE-100 In The Treatment Of Sarcoidosis
Up 40% Pre-Market OTLK..3.13..Outlook Therapeutics Early this morning reported positive efficacy and safety data from pivotal phase 3 Norse Two trial of ONS-2010/Lytenava TM for the treatment of wet macular degeneration
Moneymakers At Or Near 52 Week Lows VITL..17.20 LVS....41.64 ATHM...45.54 AXSM...51.25 KMPR...63.32 PRLB...79.38
News At 9 SRNE..8.34 Sorrento Mexico And The National Institute Of Genomic Medicine Of Mexico Government Execute Memorandum Of Understanding Of Covid-19 Diagnostics Therapeutics and Multivariant MRNA-Based Vaccines Against Sars-Cov-2 And Its Variants Of Concern
